Skip to content

Ligand Pharmaceuticals

US · LGND #1920 by market cap Listed 1970
286.85 -0.09 -0.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 285.01 -0.67%
After-hours 286.85 0.00%
322.75229.78286.852026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LGND?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +22.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 12.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B
ValuationGrowthProfitMomentumHealthAnalyst
Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 115.2x Better than 3%
Forward P/E 69.0x Better than 5%
Price / Sales 24.3x Better than 5%
P/E vs own 5-yr range 99th pctl Better than 3%
Growth C-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 11.0% Better than 67%
Net income CAGR (3Y) -26.4% Better than 13%
Free cash flow CAGR (3Y) -31.8% Better than 10%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 94.6% Better than 98%
Operating margin 17.6% Better than 71%
Net margin 46.4% Better than 97%
Return on equity 13.5% Better than 64%
Return on invested capital 10.2% Better than 68%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 0.2% Better than 74%
6-month return 25.1% Better than 87%
12-month return (ex latest month) 52.4% Better than 84%
Distance below 52-week high 12.2% Better than 78%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 22.2x Better than 98%
Debt to assets 28.9% Better than 43%
Interest coverage 34.7x Better than 88%
Free cash flow / net income 30.6% Better than 8%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 27.9% Better than 46%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.11%
1M -6.38%
3M -0.19%
6M +31.73%
YTD +51.72%
1Y +44.12%
3Y +393.55%
5Y +183.98%

Key statistics

Price & volume

Prev close
286.94
Open
285.21
Day range
282.36 - 291.36
Avg price
287.26
Volume
259.79K
Turnover
74.63M
Amplitude
3.14%
52-week range
175.89 - 326.63

Valuation

P/E
46.79
P/E (TTM)
115.20
P/B
5.97
EPS
6.13
Net profit
122.62M
Net assets
961.76M

Share structure

Market cap
5.74B
Float cap
5.61B
Shares out
20.00M
Float shares
19.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 74% of range
175.89 326.63

12.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+10.08M net over the window

Short interest

Shares short
2.46M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ligand Pharmaceuticals (LGND)?

Ligand Pharmaceuticals last traded at 286.85. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ligand Pharmaceuticals's market cap?

About 5.74B.

What is the P/E ratio of Ligand Pharmaceuticals?

The trailing twelve-month P/E is 115.20. The Valuation tab shows it against the stock's own five-year range.

Does Ligand Pharmaceuticals pay a dividend?

Ligand Pharmaceuticals does not currently pay a regular dividend.

Is Ligand Pharmaceuticals a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 367.00, which implies 27.9% upside from the current price. This is not investment advice.

What is Ligand Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ligand Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ligand Pharmaceuticals discussion 0 comments

Add a comment